CORT Earnings

CORT reported its earnings on 2026-04-30, showcasing a revenue of 164.90M against an estimate of 172.43M, resulting in a -4.37% surprise. The EPS was -0.3, surpassing the expected -0.3 by 0%. The stock experienced a 10.53% price change on the earnings day and a 12.1% change over the next five days, reflecting market reactions to the results.

Following CORT's earnings announcement on 2026-04-30, the stock price moved by 10.53% on the day of the release. Over the subsequent five days, it saw a 12.1% change. Historically, CORT's stock price tends to shift by an average of -1.07% in the 10 days leading up to earnings and 3.38% in the 10 days following, providing insight into potential market.

For 2026/Q2, analysts estimate CORT's annual revenue to reach 229.77M, while the EPS is projected at 0.11. These estimates reflect recent revisions, with revenue estimates unchanged by 0% and EPS estimates unchanged by 0% over the past three months, indicating analyst expectation in the company's performance.

The correlation between CORT's stock price and earnings forecast revisions shows that positive revisions in revenue or EPS often strengthen the stock's fundamentals. Over the past three months, revenue estimates for FY2025 were unchanged by 0%, while EPS estimates moved unchanged by 0%. This trend suggests that price dips could present buying opportunities for investors.

Based on historical trends, CORT's stock price typically moves by -1.07% in the 10 days before its earnings and 3.38% in the 10 days after. For the upcoming 2026/Q2 earnings, analysts expect an EPS of 0.11 and revenue of 229.77M.

The earnings call presents mixed signals. Financial performance shows revenue growth but a significant net loss. Product updates are promising, with positive trial results and optimistic guidance for Cushing's syndrome and oncology drugs. However, operational challenges, regulatory risks, and competitive pressures persist. The Q&A reveals confidence in relacorilant and Lifyorli but highlights market competition and supply chain issues. No share buyback or dividend program is mentioned. Considering the market cap and mixed outlook, the stock price is likely to remain stable, with a neutral sentiment over the next two weeks.